NDLI: The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China

Content Provider	Springer Nature : BioMed Central
Author	Wang, Fang Qu, Mengyuan Zhou, Xuan Zhao, Kai Lai, Changxiang Tang, Qiyuan Xian, Wenjie Chen, Ruikun Li, Xuan Li, Zhiyu He, Qing Liu, Lei
Abstract	Background The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. Methods In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People’s Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression. Results Of all the 333 patients, 70 (21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253 (76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80 [1.72, 8.52]), males (2.21 [1.20, 4.07]), with comorbidities (1.78 [1.13, 2.81]) certain exposure history (0.38 [0.20, 0.71]), abnormal radiology manifestations (3.56 [1.13, 11.40]), low level of T lymphocytes (0.99 [0.997, 0.999]), high level of NLR (0.99 [0.97, 1.01]), IL-6 (1.05 [1.03, 1.07]) and CRP (1.67 [1.12, 2.47]) were the risk factors of disease progression by logistic regression. Conclusions The potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage.
Related Links	https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/s12967-020-02423-8.pdf
Ending Page	11
Page Count	11
Starting Page	1
File Format	HTM / HTML
ISSN	14795876
DOI	10.1186/s12967-020-02423-8
Journal	Journal of Translational Medicine
Issue Number	1
Volume Number	18
Language	English
Publisher	BioMed Central
Publisher Date	2020-07-03
Access Restriction	Open
Subject Keyword	Biomedicine Medicine Public Health COVID-19 Pneumonia Clinical progression Risk factor Retrospective analysis Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Biochemistry, Genetics and Molecular Biology Medicine
Journal Impact Factor	6.1/2023
5-Year Journal Impact Factor	6.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Risk factors for severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective study

Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis

Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study.

Postpartum depression and associated risk factors during the COVID-19 pandemic

The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

CT radiomics facilitates more accurate diagnosis of COVID-19 pneumonia: compared with CO-RADS

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China

Similar Documents

Risk factors for severe COVID-19 in middle-aged patients without comorbidities: a multicentre retrospective study

Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis

Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study.

Postpartum depression and associated risk factors during the COVID-19 pandemic

The analysis of risk factors for diabetic nephropathy progression and the construction of a prognostic database for chronic kidney diseases

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

CT radiomics facilitates more accurate diagnosis of COVID-19 pneumonia: compared with CO-RADS

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China